Affordable anti-rejection drug as effective as higher cost option

October 14, 2009

A newer, less expensive drug used to suppress the immune system and prevent organ rejection in kidney and pancreas transplant patients works just as well as its much more expensive counterpart, according to a new study by researchers at Wake Forest University Baptist Medical Center.

Such discoveries are vital in an era of skyrocketing health care costs and debate over health reform, said lead investigator Alan C. Farney, M.D., Ph.D., an associate professor of surgery in the Department of General Surgery, Transplantation Services.

"I think it's very important that the public consider cost, and that they ask their doctors if there are alternatives for them that are less expensive," he said. "Why should we use one drug or intervention over another that is equally effective and a fraction of the cost?"

For the study, published recently in the journal Transplantation, researchers looked at the two most common drugs used for induction immunosuppression therapy with kidney and pancreas transplants:

  • alemtuzumab, a newer drug that costs about $1,000 per single-dose treatment and is marketed under the name CampathTM; and
  • rabbit antithymocyte globulin, which costs about four times more for its multidose treatment than alemtuzumab, and is marketed under the name Thymoglobulin(TM).
Both drugs destroy the cells that cause organ rejection during induction immunosuppression therapy - a short-term, early treatment meant to rapidly lower the immune system to prevent rejection until the patient begins taking daily drugs to suppress the immune system.

Though more expensive, rabbit antithymocyte globulin has generally been more commonly prescribed than alemtuzumab at Wake Forest Baptist and other transplant centers because there has been a concern that the newer drug would suppress the too much and lead to infections or cancer, Farney said.

"We want to avoid acute rejection, but we also don't want to pay a price when we're trying to do that by leaving the patient over-immunosuppressed," he said. "We were being cautious, but this study reveals that, through at least two years of follow up, both drugs are equally effective and safe."

In the study of 222 patients receiving either kidney transplants alone, simultaneous kidney-pancreas transplants, or pancreas-after-kidney transplants, researchers found that both drugs showed similar survival rates for the patients (96 percent), the transplanted kidneys (89 percent) and the transplanted pancreases (90 percent). The drugs also had similar infection rates.

From Feb. 1, 2005, to Sept. 1, 2007, transplant patients participating in the study received either alemtuzumab or rabbit antithymocyte globulin, followed by the same course of maintenance drugs. Both groups included patients who varied in age, race, gender and risk - a unique approach with clinical studies, which usually look at a group with similar characteristics.

The researchers wanted to design this study - one of the largest single-institution trials for transplantation drugs - to reflect the actual demographics of the Medical Center's transplant patients, Farney said. Transplantation Services at Wake Forest University Baptist Medical Center performs more than 150 kidney and pancreas transplants each year.

"It represents who we really transplant at Wake Forest Baptist," Farney said. "Other trials are so exclusive that you don't know what the true results are for most people."

As a result of the study, the Wake Forest Baptist Transplant Program has adopted the newer drug as part of its standard anti-rejection protocol for kidney and pancreas transplantation, Farney said.

Source: Wake Forest University Baptist Medical Center (news : web)


Rank 5 /5 (1 vote)
Relevant PhysicsForums posts
  • Is Everyday Technology Killing Us?
    createdFeb 08, 2012
  • Exercise and weight loss
    createdFeb 08, 2012
  • Why do we have head aches? Our brains can't feel anything.
    createdFeb 07, 2012
  • "The end of diseases" by David Agus, interview from Daily Show with Jon Stewart
    createdFeb 04, 2012
  • Oncolytic adenovirus
    createdFeb 04, 2012
  • Nutrition label stuffs and diets
    createdFeb 02, 2012
  • More from Physics Forums - Medical Sciences

More news stories

'It's not nutritious until it's eaten'

As part of her "Let's Move! Initiative," First Lady Michelle Obama unveiled a new web resource highlighting new changes in the Chefs Move to Schools, during a CMST gathering in Dallas, TX today. CMTS advocates ...

Medicine & Health / Health

created 1 hour ago | popularity not rated yet | comments 0

New ability to regrow blood vessels holds promise for treatment of heart disease

(Medical Xpress) -- University of Texas at Austin researchers have demonstrated a new and more effective method for regrowing blood vessels in the heart and limbs — a research advancement that could have ...

Medicine & Health / Research

created 1 hour ago | popularity 5 / 5 (3) | comments 0 | with audio podcast

Motivation to exercise affects behavior

(Medical Xpress) -- For many people, the motivation to exercise fluctuates from week to week, and these fluctuations predict whether they will be physically active, according to researchers at Penn State. In an effort to ...

Medicine & Health / Health

created 1 hour ago | popularity not rated yet | comments 0 | with audio podcast

New tumor suppressor gene identified

A recent study published in Clinical Cancer Research suggests that the protein hVps37A suppresses tumor growth in ovarian cancer. The work, which was funded by the Austrian Science Fund FWF, shows, for th ...

Medicine & Health / Cancer

created 2 hours ago | popularity 4.7 / 5 (3) | comments 0

Social psychologist: Lust makes you smarter and evidence that seven deadly sins are good for you

(Medical Xpress) -- Good news for lovers on Valentine’s Day - the seven deadly sins, including Lust, are good for you. University of Melbourne social psychologist Dr Simon Laham uses modern research to make a compelling ...

Medicine & Health / Psychology & Psychiatry

created 4 hours ago | popularity 3.3 / 5 (3) | comments 0


Fast photon control brings quantum photonic technologies closer

(PhysOrg.com) -- Using photons instead of electrons to transmit information could lead to faster and more secure ways to communicate, among other advantages. Now a team of physicists has taken another step toward realizing ...

Planck mission steps closer to the cosmic blueprint

(PhysOrg.com) -- ESA's Planck mission has revealed that our Galaxy contains previously undiscovered islands of cold gas and a mysterious haze of microwaves. These results give scientists new treasure to mine ...

Slowing ocean current caused Earth to spin faster

(PhysOrg.com) -- Most people probably didn’t notice it, but back in 2009, the Earth spun around on its axis a tiny bit faster than usual, making for some slightly shorter days. It only happened for a ...

Independent group inspects Apple supplier

(AP) -- An independent group, the Fair Labor Association, has started auditing Apple Inc.'s Chinese supplier Foxconn after a request by Apple.

New European rocket lifts off on maiden flight

Europe on Monday successfully launched a new lightweight rocket carrying a test payload, culminating a more than 12-year quest to master the entire range of space launchers.

New molecule has potential to help treat genetic diseases and HIV

(PhysOrg.com) -- Chemists at The University of Texas at Austin have created a molecule that's so good at tangling itself inside the double helix of a DNA sequence that it can stay there for up to 16 days before ...